Objectives: To describe the experience of a community teaching hospital emergency department (ED) Code Stroke Protocol (CSP) for identifying acute ischemic stroke (AIS) patients and treating them with tissue plasminogen activator (tPA) and to compare outcome measures with those achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial. Methods: This study was a retrospective review from a hospital CSP registry. Results: Over a 56-month period, CSP activation occurred 255 times, with 24% (n = 60) of patients treated with intravenous (IV) tPA. The most common reasons for thrombolytic therapy exclusion were mild or rapidly improving symptoms in 37% (n = 64), intracerebral hemorrhage (ICH) in 23% (n = 39), and unconfirmed symptom onset time for 14% (n = 24) of patients. Within 36 hours of IV tPA treatment, 10% (NINDS = 6%) of patients (n = 6) sustained a symptomatic ICH (SICH). Three months after IV tPA treatment, 60% of patients had achieved an excellent neurologic outcome, based on a Barthel Index of $95 (NINDS = 52%), while mortality measured 12% (NINDS = 17%). Among IV tPAtreated patients, those developing SICH were significantly older and had a significantly higher mean initial glucose value. Treatment protocol violations occurred in 32% of IV tPA-treated patients but were not significantly associated with SICH (Fisher's exact test). Conclusions: Over the study period, the CSP yielded approximately one IV tPA-treated patient for every four screened and, despite prevalent protocol violations, attained three-month functional outcomes equal to those achieved in the NINDS trial. For community teaching hospitals, ED-directed CSPs are a feasible and effective means to screen AIS patients for treatment with thrombolysis.
Since publication of the National Institute of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) trial and the Food and Drug Administration's approval of tPA as a treatment for acute ischemic stroke (AIS), concerns have been raised regarding the clinical feasibility and effectiveness of tPA treatment for AIS in routine clinical practice. [1] [2] [3] [4] Although many hospitals with abundant stroke care personnel have developed ''stroke teams'' to ensure the rapid availability of expertise and resources required to safely and effectively administer this therapy, such an option does not exist for many hospitals. [5] [6] [7] [8] [9] [10] For such hospitals, emergency department (ED)-driven treatment protocols, modeled after the NINDS tPA trial have been recommended to foster the identification and treatment of AIS patients with intravenous (IV) thombolytic therapy. [11] [12] [13] Our community teaching hospital has an academic department of emergency medicine, which relies on a private neurology group to assist in the management of AIS IV tPA candidates. Unlike many university-based hospitals, there is no ''stroke team'' to assist in the management of AIS patients. Beginning in 1997, after several months of joint planning with our neurology colleagues, a Code Stroke Protocol (CSP) was instituted in our ED to facilitate the systematic and expeditious treatment of acute stroke patients. This work describes our experience from 1997 to 2001 with our CSP for identifying and treating AIS patients eligible for thrombolytic therapy. We compared our outcome measures of IV tPA-treated AIS patients with those achieved in the NINDS trial. 1 
METHODS
Study Design. This was a retrospective review from our CSP patient registry. Our hospital's institutional review board approved this protocol.
Study Setting and Population. This study was conducted in a community teaching hospital with an ED volume of 108,000 patient visits per year. Patients included in this study were all patients presenting to the ED with AIS.
Study Protocol. In February 1997, our ED instituted a CSP to guide the evaluation of patients meeting initial screening criteria for treatment with tPA. Our protocol was developed jointly by emergency physicians (EPs), ED nurses, and neurologists from the sole private neurology group servicing our hospital. The protocol was modeled after the NINDS tPA study protocol and the guidelines established by the American Heart Association. 1, 14 The CSP is designed for activation after an EP has performed a preliminary evaluation of a patient with stroke symptoms and deemed them to meet preliminary inclusion criteria for thrombolytic treatment. The criteria for activation of the CSP are listed in Table 1 . Activation of the CSP includes all of the activities listed in Table 2 , which are carried out by the physicians and nurses working in the ED. The neurologist on call is notified as part of the CSP and routinely examines the patient prior to the decision to institute thrombolytic therapy. No formal ''stroke team'' assists in patient management. Checklist guidelines are used to verify that laboratory results meet inclusion criteria based on published guidelines. If a patient is deemed an appropriate IV tPA candidate, the patient is treated with tPA according to the guidelines published by the American Heart Association.
14 Preformatted physician orders exist that specify tPA dosing and blood pressure treatment recommendations as outlined in published guidelines. For the first 24-36 hours after tPA administration, patients were closely monitored in either a neurosurgical intensive care unit or medical intensive care unit. Standardized nursing orders, in accordance with published guidelines and including explicit instructions regarding blood pressure treatment, were used for all patients. With the exception of heparin infusion within 24 hours after tPA administration, deviations from treatment guidelines were not tracked. After announcement of the PROACT II (Prolyse in Acute Cerebral Thromboembolism) study results in December 1999, and the 2000 revision to Advanced Cardiac Life Support (ACLS), which designated intra-arterial (IA) thrombolytic therapy a level IIb recommendation, IA therapy became a treatment option within the CSP for patients for whom IA therapy could be initiated within six hours of their stroke symptom onset. 15 Demographic, process, and outcome data for IA tPA treated patients are not presented in this work.
Because our institution is a referral center for our region, some AIS patients are transferred to our facility for further treatment and neurologic evaluation. The decision to transfer a patient and/or treat him or her with tPA is usually made jointly by the local treating EP, a study hospital EP, and a consultant neurologist; however, no formalized procedure exists for making this decision. Transferring medical facilities have not been selectively recruited, and in only one case have physicians from a transferring hospital received specialized training on our institution's CSP. All AIS patients transferred to the study institution who are treated with IV tPA prior to transfer are evaluated in the study institution ED, rather than being directly admitted to the hospital. Some patients transferred have already received IV tPA prior to arrival at the study ED. Any AIS patient transferred to our facility who has received thrombolytic therapy prior to transfer is by default enrolled in the CSP.
From the outset of implementation of our CSP, our registry has been maintained to monitor the process, treatment, and outcomes achieved by implementation Measures. Our data were compared with the results achieved in the NINDS tPA trial. 1 NINDS parts I and II refer to the two groups of patients described in this trial. NINDS part I was intended to assess changes in neurologic deficits 24 hours after the onset of stroke as a measure of the activity of tPA. NINDS part II was designed to evaluate outcomes at three months via the use of four functional outcome measures. However, the results of the two parts were combined and both groups of patients were ultimately evaluated for outcome at both 24 hours and three months. IV tPA patients at our hospital were classified as having a symptomatic intracerebral hemorrhage (ICH) based on a noncontrast head computed tomography (CT) scan performed 24-36 hours after tPA administration. The PROACT II study definition of symptomatic ICH [$4-point increase in total NIHSS or $1-point increase in loss of consciousness (LOC) subscore of NIHSS] was used to categorize study patient ICH at 36 hours as being either symptomatic or asymptomatic. 15 This definition was selected because it allows for a more objective and standardized classification of ICH than that used in the NINDS trial. Additionally, the following prespecified protocol violations were evaluated for patients treated with IV tPA: glucose \50 mg/dL or [400 mg/dL, platelet count \100,000 mm 3 , prothrombin time (PT) [15 seconds (international normalized ratio [1.7), last documented pretreatment systolic blood pressure (sBP) [185 mm Hg, last documented pretreatment diastolic blood pressure (dBP) [110 mm Hg, tPA dose [0.95 mg/kg, tPA treatment initiated [3 hours from stroke symptom onset, and heparin use within 24 hours after tPA dosing. Treatment process time intervals were compared with the IV tPA treatment time goals established by the NINDS. 16 Data Analysis. We employed standard statistical methods, including Student's t-tests, to compare interval scale data between groups and chi-square or Fisher's exact test to compare between groups for nominal data. A p-value of less than 0.05 was considered statistically significant. For the most important estimates, 95% confidence intervals (CIs) are provided. A few points regarding the statistical analyses performed are worth emphasizing. No adjustment was made for the comparison of three groups to correct or allow for an inflated type I error risk associated with the multiple comparisons. Second, we used t-tests rather than nonparametric equivalence tests when comparing our data with the NINDS data set because we did not have access to each of the observations from the NINDS data set. We recognize that our data are likely to be skewed and therefore the appropriate test would be nonparametric; however, applying a nonparametric test requires access to NINDS data that is not available. The SAS software (SAS Institute, Inc., Cary, NC) was used for analyses.
RESULTS
Over a 56-month period, the CSP was activated for 255 patients. A flow chart outlining the CSP experience of these patients is depicted in Figure 1 . For 25 patients, care was initiated in the ED of an outside institution prior to transfer to the study hospital. Twenty-four percent (n = 60) of patients enrolled in the CSP were treated with IV tPA, while 9% (n = 22) were treated via IA thrombolysis. The most common reasons for being excluded from thrombolytic therapy are shown in Figure 2 and included 37% (n = 64) of patients with minimal weakness or symptoms improving, ICH in 23% (n = 39) of patients, and onset time not confirmed to be within three hours for potential treatment for 14% (n = 24) of patients. Stroke mimics were identified as a tPA exclusion criterion in the 5% of patients and included syncope, psychogenic speech disturbance, hypertensive crisis, conversion disorder, cervical myelopathy, and mononeuritis. Baseline characteristics for patients treated with IV tPA are listed in Table 3 . Study patients were significantly younger than both NINDS I (mean difference 4 years, 95% CI = 0.9 to 7.1 years) and NINDS II patients (mean difference 6 years, 95% CI = 2.5 to 9.5 years) and had significantly lower baseline glucose measurements to those in NINDS I (mean difference 22 mg/dL, 95% CI = 1.3 to 42.7 mg/dL) and NINDS II (mean difference 22 mg/dL, 95% CI = 3.7 to 40.3 mg/ dL). Additionally, whites were less represented, while African Americans comprised significantly more patients compared with the NINDS part II patient group (mean difference 20%, 95% CI = 6.0% to 34.2%). The mean and median baseline NIHSS scores were 13.5 (66), which was nearly identical to that reported in NINDS.
Within 36 hours of IV tPA treatment, 10% of patients (n = 6) sustained a symptomatic ICH, while 5% (n = 3) sustained an asymptomatic ICH (Table 4) .
Three months after IV tPA treatment, 60% (n = 32/53) of patients were able to perform activities of daily living at an excellent level as measured by a Barthel index of $95, while mortality measured 10% (Table 4 , Figure 3 ). None of these outcome measures differed significantly from those reported in the NINDS trial.
Process data regarding achievement of NINDS time goals and adherence to NINDS tPA treatment protocol guidelines are depicted in Figure 4 and Table 5 . 1, 14, 16 In only 11% of cases was tPA administered within 60 minutes of arrival to the ED, and in 13% (n = 8/60) cases, tPA treatment was initiated beyond three hours from stroke symptom ictus. Overall, treatment protocol violations occurred in 32% (n = 19) of IV tPA-treated patients, but protocol violations were not significantly associated with subsequent ICH (Fisher's exact test).
Characteristics of IV tPA-treated patients who sustained symptomatic ICH compared with those who did not are listed in Table 6 . The mean age and initial blood glucose value of the six patients with a symptomatic ICH at 36 hours were significantly higher than those of other IV tPA-treated patients, while the presenting NIHSS score was nonsignificantly higher in patients sustaining an ICH after IV tPA treatment.
Ten percent of all CSP patients and 25% (n = 15) of all patients receiving IV tPA were transferred from referral EDs to our hospital. Most patients transferred who received IV tPA had their tPA administration started prior to transfer (66%). We found no statistically significant increased rate of either protocol violations or symptomatic ICH (SICH) in any transferred patients.
DISCUSSION
This study describes roughly the first five years of treatment and outcome experience of a community teaching hospital's protocol for managing acute stroke patients. Since the approval by the Food and Drug Administration in 1996, many university, urban, community, and rural hospitals have reported their experience with IV tPA for AIS. 10, 12, 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In most of these studies, patients were treated either at university teaching hospitals, by dedicated ''stroke teams,'' or by stroke neurologists with experience in acute stroke trials such as the NINDS tPA trial. 10, 17, 19, 20, [22] [23] [24] 27, 28 Our study describes the therapeutic yield of a protocol that does not include a ''stroke team'' and is instituted after an initial patient screen has been performed in the ED. The prescreening design of our protocol likely represents the reason for the higher percentage of patients treated with thrombolytic therapy than the 0.6-6% range reported by most other groups. 10, 13, 17, 19, 21 Koennecke et al. 27 reported treating 47% of those ''potentially eligible for thrombolytic treatment,'' but it is unclear from their report to what extent ''potentially eligible'' patients were prescreened other than presentation within three hours of symptom onset. With the exception of a slightly lower mean age and a different racial balance, the baseline characteristics of our IV tPA-treated patients compared similarly with those treated in the NINDS study. The increased percentage of African Americans in our study compared with NINDS likely is a reflection of the overall demographics of our ED population (in 2001, 57% of all patients treated in our ED were African American). Additionally, the increased African American population in our study may explain the younger average age of our patients compared with NINDS, because it is recognized that below age 65 years, African American men and women have higher rates of first and recurrent stroke compared with whites. [30] [31] [32] Our relatively high rate (23%) of hemorrhagic strokes, based on that exclusionary finding on CT, may also be explained by the racial composition of our ED stroke patients (50%, n = 18 of patients diagnosed as having intracerebral hemorrhage were African American). Our top three reasons for excluding patients from thrombolytic therapy were minor or rapidly resolving symptoms, ICH, and time limitation, which are the same as those found by other investigators. 10, [17] [18] [19] 23, 33 It is important to recognize that while minor or significantly improving neurologic symptoms may be perceived as indicative of a good neurologic outcome, Barber et al. 17 demonstrated that 32% of all such patients were either dependent at discharge or died during hospital admission. 17 While the outcomes of such patients were not followed in our study, Barber et al.'s finding is concerning. Certainly the possibility exists that physicians who are reluctant to treat with tPA, due to safety or efficacy concerns, may inappropriately apply the ''minor or significantly improving neurologic symptoms'' tPA exclusion criterion, so as to withhold therapy from patients who are really not demonstrating significant clinical improvement. Also, despite the fact that one of the criteria for activation of the CSP is symptom onset time initially determined to be within two hours of ED presentation, 14% of CSP patients could not have their symptom onset times confirmed to be within the three-hour treatment window and were deemed ineligible for thrombolysis.
27
Only about 10% of our patients treated with IV tPA were treated within 60 minutes of ED arrival, which is the recommended goal established by the NINDS, and similarly only about 30% of patients received their head CT within 25 minutes. 16 While our mean door-to-drug time of 93 minutes was quite similar to that reported by other groups, our mean time to treatment from symptom onset was beyond two and a half hours, with 98% of patients treated beyond 90 minutes of their symptom onset and 53% treated beyond 150 minutes of their stroke ictus. 10, 12 This finding highlights the reality that given typical patient ED presentation times after symptom onset and the recognition that considerable clinical activities need to be performed prior to obtaining a CT or initiating tPA treatment, the likelihood of significantly impacting future overall time to treatment is small. Others have emphasized this issue, particularly in light of recently published imbalances in the NINDS late treatment group randomization and the recognition that the treatment time window of the odds ratio for a favorable outcome may be less than that originally described. 4, 34 Although our three-month mortality of 12% was less than that found in NINDS (17%), and our SICH rate at 36 hours was 10% (NINDS 6%), these differences were not statistically significant. Other phase four trials evaluating tPA use for AIS have found SICH rates of 2% to 16%. 10, 12, [20] [21] [22] [23] [26] [27] [28] It is also important to recognize in our study that while 33% (2/6) of patients treated with IV tPA who sustained a symptomatic ICH had died at three months, an equal number had a three-month Barthel index of $95, emphasizing that a symptomatic ICH does not necessarily imply death or a poor neurologic outcome. Additionally, while a three-month Barthel index was not obtained in seven of our patients, even assuming the worst-case scenario of none of those patients having a Barthel index $95 at three months, our modified excellent neurologic result of 53% would compare similarly with NINDS (54%).
At least one protocol violation occurred in almost every three patients treated with tPA, but there was no statistically significant association between the presence of protocol violations and symptomatic ICH. Varied results have been previously reported regarding the association of protocol violations to symptomatic ICH or other complications. 21, 22, 24, 26, 35 In a retrospective survey of hospitals experienced in treating AIS with tPA, Tanne et al. 24 found 21, 24 Additionally, the Standard Treatment with Alteplase to Reverse Stroke (STARS) investigators found protocol violations in 33% of 389 AIS patients treated with tPA in both academic and community hospitals but found no significant difference in SICH rates between patients with and without protocol violations. 22 Alternatively, other groups have found a significant association between protocol violations and SICH. 26, 35 These contradictory findings may be explained by the relative prevalence, importance, and severity of the different protocol violations evaluated. For example, half (4/8) of our study's time protocol violations occurred within 10 minutes of the threehour limit that defined a protocol violation. It is important to recognize from a continuous quality improvement perspective that all of our protocol violations occurred at the point when tPA administration was initiated, suggesting that particular attention needs to be directed to issues such as the blood pressure treatment and tPA dosing guidelines as tPA administration is about to begin. Alternatively, protocol violations such as laboratory exclusion criteria, which do not necessarily require specific attention at the moment prior to tPA infusion, never occurred in our study. The need to specifically acknowledge those laboratory exclusion criteria within our protocol and written orders that remind physicians and nurses to withhold aspirin or heparin in potential tPA candidates are likely beneficial attributes of our protocol, since none of those protocol violations occurred. To more definitively identify risk factors associated with symptomatic ICH, a sample size substantially larger than that included in this report would likely be required.
Due to the small number of patients with symptomatic ICH after tPA in our study (n = 6), it is somewhat hazardous to attempt to identify risk factors for hemorrhagic conversion, but in univariate analysis, increased age and glucose level were found to be significantly associated with symptomatic ICH. Although advanced age has been previously reported to be associated with increased risk of ICH after thrombolysis, other groups have not found this association. 21, 36, 37 Other than age, the only characteristic significantly different in symptomatic ICH patients was glucose level, with hyperglycemia associated with symptomatic ICH. This finding has been observed by other investigators. 21, 38 In a study of 138 diabetic and nondiabetic patients with AIS treated with IV tPA, Demchuk et al. 38 found that higher admission serum glucose level was associated with a higher risk of hemorrhagic conversion of the infarct. Additionally, while it is unclear from Katzan et al.'s report 21 exactly when the glucose measurements they reported were taken relative to when tPA was administered, their mean ''highest reported glucose'' was 199 mg/dL in patients who sustained symptomatic ICH. The association of a tendency for higher serum glucose levels in patients with larger infarcts may explain why hyperglycemia is associated with ICH after tPA, since based on NIHSS, larger infarcts appear more likely to bleed after tPA. 36, 39, 40 The fact that the NIHSS score nonsignificantly tended to be higher in our patients with SICH supports this theory. Alternatively, several histochemical and metabolic theories may explain why hyperglycemia predisposes to ICH after tPA. [41] [42] [43] [44] [45] 
LIMITATIONS
An important question to consider is the impact of the neurologist's involvement in the CSP. While our study was not specifically designed to address this issue, a few comments are worth emphasizing. The neurologist on call is notified as part of the CSP and is always consulted prior to the administration of thrombolytic therapy. For patients initially presenting to the study hospital, a neurologist always examines any patient ultimately deemed a candidate for thrombolytic therapy; however, for some patients transferred to the study hospital, telephone consultation is the sole involvement of the neurologist prior to tPA administration. The impact of the neurologist on decision making specifically related to tPA administration is unknown.
Regarding the necessity of having a neurologist examine every patient prior to tPA administration, we believe this is strongly preferred by all, and a requirement for most, EPs. While we did not specifically track whether having a neurologist examine every patient who receives tPA caused delays in thrombolytic administration, our quality assurance processes have not identified any instances of a delay in tPA administration specifically related to unavailability or delayed arrival of the neurologist on call. It is important to emphasize, however, that prior to instituting the CSP, the neurology group covering the study hospital agreed to provide timely response to all CSP activations.
As a retrospective study from our stroke registry, the possibility exists for selection bias, inflating the yield of the CSP or positive outcomes. However, to the best of our knowledge, data have been collected and are reported on all patients for whom the CSP was activated during the study period. While data extractors were not systematically blinded to patients' outcomes, using a standardized data collection sheet and guidelines for data abstraction enhanced uniformity of data collection. Transferring medical facilities were not selectively recruited, and in only one case did physicians at those hospitals receive specialized training on the study institution's CSP. While this leads to some heterogeneity in the final CSP population, our intention was to report the experience of all IV tPA-treated patients coming through our ED, rather than the subset that initially presented only to our institution. Further information about transferring facilities, such as the percentage of stroke patients they transfer or the level of involvement of the neurologist on call at that institution, is unknown. We did not report our outcomes with IA treated patients because our registry was initially designed to only track our experience with IV tPA-treated patients. Our registry now has expanded, and we hope to report our results with IA-treated patients in the future. Finally, since this study did not include a control group, it provides no evidence on the efficacy of treatment, but it supports the feasibility of using IV tPA in a community teaching hospital without an academic neurology service. While our institution does not have a designated ''stroke team,'' we are fortunate to have neurologic and neuroradiological support that does not exist at many hospitals. The feasibility of our approach at such hospitals would be worth investigating.
CONCLUSIONS
This study demonstrates that during the first five years of implementation, our ED's CSP yielded approximately one IV tPA-treated patient for every four screened. Despite prevalent protocol violations, the CSP attained three-month functional outcomes and mortality equal to or better than those achieved in the NINDS trial. While measures must be taken to improve adherence to our protocol and national treatment guidelines, our results support continued use of our protocol to screen AIS patients for potential thrombolytic therapy. For hospitals without the availability of stroke teams, an ED-driven protocol including neurologic consultation represents a feasible and effective alternative for identifying and treating AIS patients eligible for thrombolytic therapy.
